I assume "hunk" = "think"? A company with clinical trials in progress for 3 totally different drugs (4 different applications) ought to have a market cap of a lot more than 100 million or so. I think the company would be valued more fairly as compared to other small biotechs at a minimum of 5/share right now. How far it can travel depends on which and how many of its drugs strikes a partnership deal and/or is approved by the FDA.

You might want to go to the company website and read the blogs. They're very informative about the progress the company's making, and what the need for the drugs is.